Norinchukin Bank’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.13M Sell
9,834
-145
-1% -$98.7K 0.06% 175
2026
Q1
$7.71M Buy
9,979
+347
+4% +$266K 0.09% 129
2025
Q4
$7.43M Buy
9,632
+821
+9% +$558K 0.09% 131
2025
Q3
$4.95M Sell
8,811
-343
-4% -$194K 0.07% 162
2025
Q2
$4.81M Buy
9,154
+776
+9% +$433K 0.07% 166
2025
Q1
$5.31M Buy
8,378
+2,568
+44% +$1.77M 0.1% 133
2024
Q4
$4.14M Buy
5,810
+475
+9% +$399K 0.09% 137
2024
Q3
$5.61M Buy
5,335
+732
+16% +$815K 0.13% 100
2024
Q2
$4.84M Buy
4,603
+32
+0.7% +$31K 0.14% 95
2024
Q1
$4.4M Sell
4,571
-136
-3% -$129K 0.13% 101
2023
Q4
$4.13M Sell
4,707
-668
-12% -$550K 0.1% 107
2023
Q3
$4.42M Sell
5,375
-5,610
-51% -$4.41M 0.1% 107
2023
Q2
$7.89M Buy
10,985
+2,568
+31% +$1.98M 0.13% 117
2023
Q1
$6.92M Buy
8,417
+221
+3% +$167K 0.14% 105
2022
Q4
$5.91M Sell
8,196
-1,858
-18% -$1.37M 0.13% 116
2022
Q3
$6.93M Buy
10,054
+977
+11% +$615K 0.14% 106
2022
Q2
$5.37M Sell
9,077
-1,959
-18% -$1.27M 0.11% 122
2022
Q1
$7.71M Buy
11,036
+1,065
+11% +$674K 0.1% 122
2021
Q4
$6.3M Sell
9,971
-531
-5% -$326K 0.08% 132
2021
Q3
$6.36M Buy
10,502
+616
+6% +$382K 0.09% 131
2021
Q2
$5.52M Buy
9,886
+130
+1% +$65.9K 0.08% 132
2021
Q1
$4.62M Buy
9,756
+465
+5% +$226K 0.06% 142
2020
Q4
$4.49M Sell
9,291
-11
-0.1% -$5.94K 0.06% 137
2020
Q3
$5.21M Buy
9,302
+609
+7% +$369K 0.08% 119
2020
Q2
$5.42M Buy
8,693
+1,643
+23% +$933K 0.09% 108
2020
Q1
$3.44M Sell
7,050
-3,853
-35% -$1.59M 0.07% 136
2019
Q4
$4.09M Sell
10,903
-875
-7% -$294K 0.05% 191
2019
Q3
$3.27M Buy
11,778
+418
+4% +$124K 0.05% 244
2019
Q2
$3.56M Sell
11,360
-3,821
-25% -$1.27M 0.05% 217
2019
Q1
$6.23M Buy
15,181
+701
+5% +$289K 0.08% 164
2018
Q4
$5.41M Buy
14,480
+4,514
+45% +$1.65M 0.08% 167
2018
Q3
$4.03M Buy
9,966
+1,202
+14% +$457K 0.05% 184
2018
Q2
$3.02M Buy
8,764
+1,688
+24% +$528K 0.05% 199
2018
Q1
$2.44M Buy
7,076
+916
+15% +$319K 0.04% 207
2017
Q4
$2.32M Buy
6,160
+441
+8% +$179K 0.04% 206
2017
Q3
$2.56M Buy
5,719
+431
+8% +$205K 0.05% 210
2017
Q2
$2.6M Buy
5,288
+346
+7% +$151K 0.05% 191
2017
Q1
$1.92M Buy
4,942
+355
+8% +$132K 0.04% 240
2016
Q4
$1.68M Buy
4,587
+545
+13% +$207K 0.04% 244
2016
Q3
$1.63M Sell
4,042
-49
-1% -$19.7K 0.04% 242
2016
Q2
$1.43M Buy
4,091
+84
+2% +$32.4K 0.03% 248
2016
Q1
$1.44M Buy
4,007
+380
+10% +$157K 0.04% 245
2015
Q4
$1.97M Sell
3,627
-797
-18% -$432K 0.05% 187
2015
Q3
$2.06M Buy
4,424
+156
+4% +$83.8K 0.05% 195
2015
Q2
$2.18M Sell
4,268
-105
-2% -$51.2K 0.06% 195
2015
Q1
$1.97M Hold
4,373
0.05% 215
2014
Q4
$1.79M Buy
4,373
+1,411
+48% +$555K 0.04% 215
2014
Q3
$1.07M Sell
2,962
-11
-0.4% -$3.69K 0.03% 208
2014
Q2
$840K Sell
2,973
-285
-9% -$84.5K 0.02% 218
2014
Q1
$978K Buy
3,258
+324
+11% +$99.8K 0.03% 208
2013
Q4
$808K Buy
2,934
+4
+0.1% +$1.15K 0.02% 221
2013
Q3
$917K Buy
2,930
+284
+11% +$74.7K 0.03% 187
2013
Q2
$595K Buy
+2,646
New +$616K 0.02% 227

Other funds holding REGN

Norinchukin Bank's REGN Position: Q2 2026 in Review

Norinchukin Bank reduced its Regeneron Pharmaceuticals (REGN) stake by 1.5% in Q2 2026, selling an estimated $98.7K and leaving 9,834 shares worth $6.13M. The position accounts for 0.06% of the portfolio, ranked #175.

Norinchukin Bank first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $7.89M in Q2 2023. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Norinchukin Bank held 9,834 shares of Regeneron Pharmaceuticals worth $6.13M as of Q2 2026.
  • Norinchukin Bank sold 145 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $98.7K.
  • Regeneron Pharmaceuticals made up 0.06% of Norinchukin Bank's portfolio in Q2 2026, its #175 holding.
  • Norinchukin Bank first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Norinchukin Bank's Regeneron Pharmaceuticals position peaked at $7.89M in Q2 2023.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Norinchukin Bank's 13F filing for Q2 2026, filed 14 Aug 2026.